Key result
Intravenous thrombolysis yields ~2.6-fold higher 90-day favorable outcomes in basilar artery occlusion.
Why the study?
The benefit of intravenous thrombolysis before endovascular therapy in basilar artery occlusion is uncertain, and whether thrombus length modifies this treatment effect was unknown.
Does thrombus length modify the treatment effect of intravenous thrombolysis on favorable 90-day functional outcome (modified Rankin Scale score 0-3) in patients with basilar artery occlusion?
RCT (n=282)
Randomized
Yes
Does thrombus length modify the treatment effect of intravenous thrombolysis on favorable 90-day functional outcome (modified Rankin Scale score 0-3) in patients with basilar artery occlusion?
In patients with basilar artery occlusion, longer thrombus length (≥7.5 mm) is associated with worse prognosis, but patients with thrombi ≥13 mm derive substantial benefit from intravenous thrombolysis.
Answers are grounded in this paper and cite their sources.
Thrombus length measurement may refine IV thrombolysis decisions in basilar occlusion; extends BASICS RCT by identifying a treatment modifier.
BACKGROUND: The benefit from intravenous thrombolysis (IVT) before endovascular therapy in patients with basilar artery occlusion is uncertain. We assessed whether thrombus length modifies the effect of IVT in patients from the BASICS trial (Basilar Artery International Cooperation Study). METHODS: BASICS was a multicenter randomized controlled trial comparing endovascular therapy plus best medical management versus medical management alone in basilar artery occlusion. We determined thrombus length on baseline computed tomography angiography and utilized receiver operating characteristic analysis to stratify cutoff values as additional covariates using regression modeling. We calculated adjusted odds ratios (aORs) for favorable outcome (modified Rankin Scale score 0–3 at 90 days) and performed interaction analyses. RESULTS: Among 300 BASICS patients, 282 had complete imaging data (median age, 69 [interquartile range, 60–76], National Institutes of Health Stroke Scale score, 22 [interquartile range, 11–35], IVT in 226 [80.1%], endovascular therapy in 145 [51.4%]). In multivariable analysis, thrombus length ≥7.5 mm (aOR, 0.51 [95% CI, 0.27–0.99]), age (odds ratio, 0.97 [95% CI, 0.95–1.00]), and National Institutes of Health Stroke Scale score (odds ratio, 0.91 [95% CI, 0.89–0.94]) were negatively, and IVT (odds ratio, 2.61 [95% CI, 1.07–6.37]) was positively associated with favorable outcome, whereas endovascular therapy was not (aOR, 1.27 [95% CI, 0.67–2.38]). Interaction analysis suggested increasing IVT benefit with longer thrombi (interaction odds ratio, 1.23; P =0.053). Although IVT showed no benefit with thrombi <13 mm (aOR, 1.27 [95% CI, 0.43–3.79]), IVT was strongly associated with favorable outcome with thrombi ≥13 mm (aOR, 12.24 [95% CI, 1.39–108.23]). CONCLUSIONS: IVT and thrombus length were associated with favorable outcome in patients with basilar artery occlusion. Although longer thrombi were generally linked to worse prognosis, our findings suggest that patients with longer thrombi may derive particular benefit from IVT.
No takes yet. Share an insight, caveat, or question.
Arndt et al. (2026) conducted an RCT in Basilar artery occlusion (n=282). Intravenous thrombolysis (IVT) stratified by thrombus length vs. No intravenous thrombolysis / thrombus length <13 mm vs ≥13 mm was evaluated on Favorable outcome (modified Rankin Scale score 0–3 at 90 days) (OR 2.61, 95% CI 1.07-6.37). Intravenous thrombolysis increased 90-day favorable outcome in basilar artery occlusion, especially with thrombi ≥13 mm.
Synapse has enriched 10 related papers. Consider them for comparative context: